BioSpace - Update on the Novel Coronavirus
The Eurofins’ U.S. Clinical Diagnostics network has launched an Antibody Test for hospital workers, first responders and patients. Testing will occur at Boston Heart Diagnostics, a Eurofins subsidiary.
FierceBiotech - Eurofins lays out plans for high-throughput COVID-19 antibody blood testing
Global testing company Eurofins announced it will begin offering large-scale, blood-based COVID-19 antibody testing in Massachusetts through its Viracor and Boston Heart Diagnostics subsidiaries.
Starting April 6, hospitals on the East Coast will be able to ship blood samples to Boston for analysis, according to Eurofins, which expects to start processing 200 tests per hour, or about 4,800 per day. Additionally, Viracor said it plans to offer its own test in mid-April.
The Doctor's Farmacy - Dr. Hyman Podcast: What You Need to Know About COVID-19 Testing with Dr. Steve Kleiboeker
Viracor's Dr. Steve Kleiboeker talks with Dr. Hyman on the The Doctor's Farmacy about who should be tested for COVID-19, when, and how, and what kinds of tests are currently available or soon will be. In addition, they discuss some of the most confusing COVID-19 recommendations, like if the general public should wear masks as a protective measure.
Boston Herald - Eurofins' Massachusetts lab launches coronavirus antibody test
Eurofins U.S. Clinical Diagnostics Network's Boston Heart Diagnostics has launched a coronavirus COVID-19 antibody blood-based test for area hospitals—where the need is the highest ahead of an anticipated surge in the coming weeks. The serology lab test may be able to identify if a person is immune to the highly contagious disease and could be the key in fighting the spread of the virus.
Eurofins’ U.S. Clinical Diagnostics Network Launches Coronavirus (COVID-19) Antibody Testing
The Eurofins’ U.S. Clinical Diagnostics network announced today that blood-based antibody testing for Coronavirus SARS-CoV-2 will begin Monday, April 6 at Boston Heart Diagnostics, a Eurofins subsidiary. Given the overwhelming demand in acute care settings, the laboratories will initially offer the test to hospitals only. As capacity increases, and as knowledge on the disease develops, the Eurofins’ network plans to begin offering testing more broadly